Medical Devices
Biologics

Kuros Biosciences lifts 2026 guidance after 40% sales rise

The Swiss bone-graft company raised full-year revenue growth guidance to 36-40% after nine-month sales hit USD 141.8 million.
The Swiss bone-graft company raised full-year revenue growth guidance to 36-40% after nine-month sales hit USD 141.8 million.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Rezolute completes enrolment in Phase 3 upLIFT tumour HI study

Rezolute has fully enrolled its 16-participant upLIFT trial of ersodetug in tumour hyperinsulinism, with topline data expected mid-December 2026.
Rezolute has fully enrolled its 16-participant upLIFT trial of ersodetug in tumour hyperinsulinism, with topline data expected mid-December 2026.
The Biotech Times Editorial Team  · 
Digital Health

WHOOP launches Arabic-language app to accelerate GCC growth

WHOOP has released a fully redesigned Arabic app and supporting campaign across the GCC, where membership is up over 75% year-on-year.
WHOOP has released a fully redesigned Arabic app and supporting campaign across the GCC, where membership is up over 75% year-on-year.
The Biotech Times Editorial Team  · 
Genomics
Diagnostics

Abu Dhabi Biobank and Cleveland Clinic tie up on UAE cancer biobank

The partnership will collect tumour and blood samples from cancer patients to build a sequenced biobank resource supporting personalised oncology research in the region.
The partnership will collect tumour and blood samples from cancer patients to build a sequenced biobank resource supporting personalised oncology research in the region.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Alaunos acquires Velaris and raises $350m to pursue PAH pipeline

Alaunos Therapeutics has completed its acquisition of Velaris and closed a $350m private placement to advance a four-asset pulmonary hypertension biologics portfolio.
Alaunos Therapeutics has completed its acquisition of Velaris and closed a $350m private placement to advance a four-asset pulmonary hypertension biologics portfolio.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Cognition Therapeutics secures polymorph patent for zervimesine to 2045

The USPTO has granted Cognition a composition of matter patent on a crystalline form of zervimesine, with a potential extension to 2050 on FDA approval.
The USPTO has granted Cognition a composition of matter patent on a crystalline form of zervimesine, with a potential extension to 2050 on FDA approval.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Agomab doses first patient in Phase 2b NOV-ERA fibrotic Crohn's trial

Agomab's global NOV-ERA study will enrol 320 patients with fibrostenosing Crohn's disease, testing ontunisertib across three dose levels.
Agomab's global NOV-ERA study will enrol 320 patients with fibrostenosing Crohn's disease, testing ontunisertib across three dose levels.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

InnoCare wins CDE nod for Phase III mesutoclax combo in r/r MZL

China's NMPA has approved a registrational Phase III study of InnoCare's BCL2 inhibitor mesutoclax plus orelabrutinib in relapsed or refractory marginal zone lymphoma.
China's NMPA has approved a registrational Phase III study of InnoCare's BCL2 inhibitor mesutoclax plus orelabrutinib in relapsed or refractory marginal zone lymphoma.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals
Digital Health

Zealand Pharma and Generate Biomedicines partner on AI protein drugs

Zealand Pharma will pay Generate Biomedicines $30m upfront, with milestones of nearly $1.2bn, to design AI-engineered multispecific proteins for obesity and metabolic
Zealand Pharma will pay Generate Biomedicines $30m upfront, with milestones of nearly $1.2bn, to design AI-engineered multispecific proteins for obesity and metabolic
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

SAB BIO wins FDA Fast Track for SAB-142 in Stage 3 type 1 diabetes

SAB Biotherapeutics has secured Fast Track designation for its human anti-thymocyte immunoglobulin SAB-142, with trial enrolment expected to complete by end of 2026.
SAB Biotherapeutics has secured Fast Track designation for its human anti-thymocyte immunoglobulin SAB-142, with trial enrolment expected to complete by end of 2026.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Oorja Bio screens first patient in Phase 2 IPF trial of ORJ-001

The Houston biotech, backed by a16z and Westlake BioPartners, has dosed its first patient in the ORBIT-IPF study of its AEC2-targeting peptide candidate.
The Houston biotech, backed by a16z and Westlake BioPartners, has dosed its first patient in the ORBIT-IPF study of its AEC2-targeting peptide candidate.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Biomea Fusion reports Phase 1 weight-loss data for oral GLP-1 BMF-650

Biomea's small-molecule GLP-1 receptor agonist showed up to 3.2% weight reduction at Day 29 in outpatient cohorts, with a favourable tolerability
Biomea's small-molecule GLP-1 receptor agonist showed up to 3.2% weight reduction at Day 29 in outpatient cohorts, with a favourable tolerability
The Biotech Times Editorial Team  · 
Subscribe to